Yazar "Karadag, Serhat" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    CHARACTERISTICS AND SURVIVAL DATA OF PATIENTS WITH PRIMARY FOCAL SEGMENTAL SEGMENTAL GLOMERULOSCLEROSIS: TSN-GOLDMULTI-CENTER STUDY
    (Oxford Univ Press, 2023) Dheir, Hamad; Cebeci, Egemen; Karadag, Serhat; Yildiz, Abdulmecit; Guller, Nurana; Altiparmak, Mehmet Riza; Eren, Necmi
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Post-COVID-19 outcomes of non-dialysis dependent chronic kidney disease patients: a national, multicenter, controlled study
    (Springer, 2023) Karadag, Serhat; Ozturk, Savas; Arici, Mustafa; Gorgulu, Numan; Akcali, Esra; Pembegul, Irem; Taymez, Dilek Guven
    Purpose Coronavirus disease 2019 (COVID-19) has a higher mortality in the presence of chronic kidney disease (CKD). However, there has not been much research in the literature concerning the outcomes of CKD patients in the post-COVID-19 period. We aimed to investigate the outcomes of CKD patients not receiving renal replacement therapy. Methods In this multicenter observational study, we included CKD patients with a GFR < 60 ml/min/1.73 m(2) who survived after confirmed COVID-19. Patients with CKD whose kidney disease was due to diabetic nephropathy, polycystic kidney disease and glomerulonephritis were not included in this study. CKD patients with similar characteristics, who did not have COVID-19 were included as the control group. Results There were 173 patients in the COVID-19 group and 207 patients in the control group. Most patients (72.8%) were treated as inpatient in the COVID-19 group (intensive care unit hospitalization: 16.7%, acute kidney injury: 54.8%, needing dialysis: 7.9%). While there was no significant difference between the baseline creatinine values of the COVID-19 group and the control group (1.86 and 1.9, p = 0.978, respectively), on the 1st month, creatinine values were significantly higher in the COVID-19 group (2.09 and 1.8, respectively, p = 0.028). Respiratory system symptoms were more common in COVID-19 patients compared to the control group in the 1st month and 3rd month follow-ups (p < 0.001). Mortality at 3 months after the diagnosis of COVID-19 was significantly higher in the COVID-19 group than in the control group (respectively; 5.2% and 1.4%, p:0.037). Similarly, the rate of patients requiring dialysis for COVID-19 was significantly higher than the control group (respectively; 8.1% and 3.4%, p: 0.045). Conclusions In CKD patients, COVID-19 was associated with increased mortality, as well as more deterioration in kidney function and higher need for dialysis in the post-COVID-19 period. These patients also had higher rate of ongoing respiratory symptoms after COVID-19.
  • Küçük Resim Yok
    Öğe
    Post-COVID-19 Outcomes of Patients with Primary Glomerular Diseases: A Nationwide Controlled Study
    (Aves, 2024) Ozturk, Savas; Karadag, Serhat; Arici, Mustafa; Turkmen, Aydin; Turgutalp, Kenan; Aktas, Nimet; Kazancioglu, Rumeyza
    Background: Patients with chronic diseases such as chronic kidney disease (CKD) have been reported to have more adverse outcomes during the coronavirus disease 2019 (COVID-19) pandemic. There are insufficient data on the outcomes of patients with primary glomerular diseases (PGD) after COVID-19. Methods: We designed a national multicenter observational study that included adult patients with biopsy -proven PGD who survived COVID-19. A control group was created from the same centers, including PGD patients without COVID-19. The clinical and laboratory data of the patients at baseline, first, and third months after COVID-19 were recorded. Results: A total of 129 patients from 21 centers were included (COVID-19 group, n = 77). Baseline characteristics were almost similar except the ratio of active disease in the non-COVID-19 group was significantly higher than in the COVID-19 group. No patients died during the first and third months. Respiratory symptoms were significantly higher in the COVID-19 group than in the non-COVID-19 group in the first month (7.8% vs. 0%, P = .039). All other follow-up outcomes, including initiation of chronic kidney replacement therapy and initiation of new immunosuppressive treatment, and the laboratory data were not different between the groups in the first and third months. Conclusion: Primary glomerular disease patients in the post-COVID-19 period had more respiratory symptoms than non-COVID-19 PGD patients, but outcomes, including death and initiation of kidney replacement therapy, were not different in the first and third months post COVID-19.